We investigate the personalisation and prediction accuracy of mathematical models for white blood cell (WBC) count dynamics during consolidation treatment using intermediate or high-dose cytarabine (Ara-C) in acute myeloid leukemia (AML). Ara-C is the clinically most relevant cytotoxic agent for AML treatment.
Author summary
The major obstacle in accurately predicting the outcome of a medical therapy is the vast variation in individual response patterns. It concerns both the subjective experience of the patient and the objectively measurable achievement of a clinical remission with restoration of normal blood counts. Here, we address acute myeloid leukemia (AML)-chemotherapy using cytarabine (Ara-C) as this drug is this most important component of AML-treatment. In addition to the wide spectrum of genetic aberrations involved in pathogenesis leading to variations in patient response patterns, another facet of personalised medicine awaits exploration of its full potential: a systematic, mathematical approach to understand and manipulate the dynamics of relevant biomarkers. We use personalised mathematical models to describe and predict white blood cell (WBC) counts during AML consolidation treatment. We analyse why and to what extent low WBC counts, a serious adverse event during therapy, occur. In a comprehensive approach we investigate published models, compare them with our extended models and outline the impact of modelling assumptions and varying chemotherapy schedules on prediction accuracy and model discrimination. Our numerical results confirm the clinical finding that a newly proposed schedule is superior with respect to WBC recovery and shed new light on the reasons why. when the WBC count recovers above 1G/L) for different Ara-C schedules and compared 48 them to published average WBC recovery times.
Methods

50
There are many different levels on which hematopoiesis and dynamics of leukemic cells 51 can be modelled [10, [18] [19] [20] . We analysed models that capture only the most important 52 dynamics for non-leukemic cells and "agglomerate" different physiological effects into 53 simplifying expressions. Leukemic cell dynamics are not considered because of the lack 54 of events (no measurable leukemic cells are present) and because of our focus on WBC 55 recovery. The necessary model extensions to analyse relapse of leukemic cells are also 56 beyond the scope of this paper. All model variations are based on the gold-standard 57 model for myelosuppression developed by Friberg et al. [6] and are tailored to the special 58 case of Ara-C via a parameterised two-compartment PK model. The personalised 59 mathematical models (PMs) were generated by estimating model parameters from 60 clinically measured WBC counts. To get a better understanding of the relation between 61 modelling hypotheses and individual predictions, we used a point estimator approach. 62 We also provide results of a population based estimation for verification and reference. 63 The procedure is described in detail below. The mathematical approaches to 64 parameter estimation, uncertainty quantification, and statistical analysis, the 65 mathematical equations, the different initial condition strategies, the PK model and the 66 nonlinear mixed-effects modelling approach are described in Appendix S1.
67
Mathematical Models
68
In the interest of providing a solid mathematical basis for future extensions we focused 69 on the most important dynamical features. There are interesting recent extensions and 70 ideas as possible additional effects of Ara-C [16, 17] , inclusion of growth factors [1] , or 71 modelling also leukemic stem cells [20] . Higher levels of detail come at the price of an 72 increased number of model parameters, which have to be estimated to obtain PMs. The 73 current lack of clinical measurements of leukemic cells or drug and growth factor 74 concentrations leads to identifiability issues with these additional model parameters. 75 Thus we concentrated on agglomerating effects of Ara-C on proliferation and 76 maturation rates. 
79
They differ concerning the number of transition compartments (M1-M3), initial 80 conditions for the differential equations (M3-M5), and model assumptions for the 81 possible effects of Ara-C on proliferation and maturation rates (M5-M12). After 82 intermediate evaluations of accuracies we concentrated on the most promising choice of 83 scaling, transition compartments, and initial conditions, and included different 84 modelling assumptions in the models M6-M12 which are alternatives to M5, our Ara-C 85 extension of the gold-standard model for myelosuppression [6] . Most models refer to 86 previous approaches in the literature and are included for a comprehensive comparison 87 and evaluation of our new hypotheses.
Proliferating cells x pr
Transit cells x tr,1 . . . x tr,ntr
Schematic model from which all mathematical models were derived. We assumed clustering of cells and cytarabine (Ara-C) concentrations in compartments with identical properties. White blood cell (WBC) differentiation is represented by a proliferating compartment x pr , a number n tr of transit compartments x tr with different levels of maturation, and a compartment x ma with mature, circulating WBC. Cells mature with a maturation rate G. Mature cells x ma are dying by the process of apoptosis with a death rate of k ma . The pharmacodynamic effect of Ara-C is described as a log-linear function E targeting the proliferating cells in the bone marrow. It depends on the concentration x 1 of Ara-C in an assumed central compartment including the circulating blood. The proliferation rate F of x pr models the replication speed of proliferating progenitor cells. Modelling assumptions were incorporated by choosing different functions F and G (compare Table 1 ). The estimated model parameters used for personalisation were B, slope, k tr , γ, and initial conditions. daunorubicin in the induction treatment for AML [8] , to a physiologically based PK 98 model for the induction therapy of AML patients with daunorubicin and Ara-C 99 (low-dose) [23] , to a combination therapy of carboplatin, etoposide and thiotepa [24] , to 100 paclitaxel [10], to an individual-based approach [25], and to drug specific 101 optimisations [9] . The model assumes a clustering of cells in compartments with 102 identical properties. WBC differentiation is represented by a proliferating compartment 103 x pr , a number n tr of transit compartments x tr with different levels of maturation, and a 104 compartment x ma with mature, circulating WBC. Cells mature with a maturation rate 105 constant G = k tr . Mature cells x ma are dying by the process of apoptosis with a death 106 rate constant k ma . As Monte Carlo simulations were not very sensitive, we fixed k ma to 107 a constant value as previously proposed [7] .
108
Apart from different PK models which were linked to the myelosuppression model, 109 also modifications of the structural model were proposed [10, 11] . Both models have a 
Modelling hypotheses from gold-standard model [6] .
As M1, with n tr = 3 transition compartments.
As M1, with n tr = 1 transition compartments.
As M3, but with more freedom to choose initial values.
As M5, but assuming a direct killing effect of Ara-C on the proliferating cells.
As M5, but replacing k tr by k tr /S(x 1 ) throughout.
As M5, but replacing F by F/S(x 1 ).
As M8, but also multiplying γ with S(x 1 ).
As M5, but multiplying γ with S(x 1 ), possibly via macrophage activation.
M11
I3
(1 − E) k tr (B bm /(0.01 * x pr + 0.99 * x tr )) γ k tr
As M5, but feedback depends on bone marrow precursor WBC instead of WBC. We used a two-compartment PK model of high-dose Ara-C, which is administered in 117 the consolidation phase, with zero-order input and linear elimination based on published 118 drug concentration-time data [26] . The corresponding parameters k 10 , k 12 , k 21 , V C were 119 estimated and defined as constants for all further computations. A two-compartment 120 PK model representing a central and peripheral compartment, see Fig 1, two-compartment PK model for low-dose Ara-C in the induction treatment for AML [8] 124 our clearance and central volume estimates are 40-50% lower, but within the 125 inter-individual variability (IIV) [8] , compare the Appendix S1. Due to the fact that 126 the drug concentration-time data from Figure 2 [26] is not assigned to the patients, the 127 IIV on the clearance and on the central volume from [8] was used for and applied on our 128 PK model to analyse the effect of the PK variability on the different modelling 129 hypotheses in the population approach. A more detailed discussion of the PK model 130 and the comparison with two recently published PK models [8, 27] can be found in the 131 Appendix S1. The body surface area BSA and the chemotherapy treatment 132 u/duration were individually fixed by clinical procedure. The PD linking the PK model 133 to the myelosuppression model was modelled by a log-linear function [11] 134 E = slope ln (1 + c V x 1 ), using the parameter slope for patient-specific calibration and 135 chemotherapeutical effects and the constant c V for unit consistency (see Table S3 ). 136 We also implemented a linear PD function with discouraging results. Additionally, we 137 tested a (sigmoid) E max model without achieving better model accuracies. proliferation rate k tr of x pr with a feedback term (B/x ma ) γ that leads to higher rates if 143 the number of circulating cells x ma is below the baseline WBC count B, and vice versa. 144 The proliferation exponent γ indicates the strength or speed of this feedback. The 145 estimation parameters were B, slope, k tr , and γ plus a varying approach of initial 146 conditions. We implemented three different strategies to treat initial conditions: I1 147 assumes a steady state, I2 assumes a steady state only for the proliferating and 148 transient compartments, and I3 penalises deviations from the steady state. I2 and I3 are 149 considered as alternative initial conditions as our clinical data indicate that the steady 150 state assumption after induction phase and between the consolidation cycles may be 151 violated. These two approaches may also account for disease progression effects. A 152 specification of I1, I2, I3 and a discussion of the number of compartments can be found 153 in the Appendix S1. We used I1 and n tr = 6 for M1, I1 and n tr = 3 for M2, I1 and 154 n tr = 1 for M3, I2 and n tr = 1 for M4, and I3 and n tr = 1 for M5-M12.
155
M6: Modelling a Direct Killing Effect of Ara-C on the Proliferating Cells
156
In the model M6, we chose the proliferation rate as discussed in previous 157 works [9, 23, 29] 
The main difference to all other models is 158 that the PD effect E is directly multiplied with x pr and not with k tr (B/x ma ) γ x pr .
159
Multiplying with x pr can be seen as a direct (killing) impact of Ara-C on the amount of 160 proliferating cells, whereas the more plausible mechanism-based rationale is the induced 161 reduction of the proliferation rate constant k tr used in all models except in M6.
162
M7-M12: Extending the Effects of Ara-C 163
The root mean squared error (RMSE) values in Table 2 indicate that model M5 with 164 one transition compartment and initial condition approach I3 provides the highest 165 accuracy after model personalisation compared to M1-M4.
166
The indirect effect of Ara-C with an impaired proliferation (M5) is more plausible Measured and calculated WBC counts were compared. The estimations and predictions used personalised mathematical models (PMs) that were calculated based on the twelve different mathematical models M1-M12. The first row refers to a personalisation for all 42 consolidation cycles (CCs). The second row shows results for personalisations using all available cycles per patient (Pat). For predictions (Pred) all but one cycle were used for personalisation and the last cycle for cross-validation. Four more rows show the predictions seperated into the different schedules (D135, d135, P D123 and P D12 ).
The RMSE values decrease from cycles to patients and from personalisation towards prediction, as expected. Comparing the mathematical models, the accuracy increases with a reduced number of compartments from M1 to M3. The initial condition strategies I2 in M4 and I3 in M5 decrease RMSEs further. M5-M12 all used n tr = 1 and I3 and performed equally well, with the slight exception of M7. Note that in particular there is no significant difference between the established gold-standard model M5 and our newly proposed extended model M10.
than a direct killing effect (M6), because Ara-CTP is incorporated into DNA and RNA and impairs cell replication [14] . Therefore, M5 became the reference model for all further analysis. We extended the proliferation rate F (·) and/or the transition rate G(·) in M5 to capture potential secondary effects of Ara-C. To understand the implications of the extensions, we observe that the proliferation rate F = (1 − E) k tr (B/x ma ) γ is negative when 1 < E. This is the case for
This corresponds to more proliferating cells being in the process of apoptosis than being in the process of cell division. It is important that the feedback term (B/x ma ) γ increases the absolute value of F for B > x ma , and decreases it for B < x ma . Therefore, an analysis of F always has to consider all four cases related to the signs of 1 − E and of B − x ma . Inspired by the log-linear behaviour of the PD effect E, we chose
This monotonously increasing function is applied to different expressions in M5.
167
In M7 we replaced the transition rate k tr by k tr /S(x 1 ) throughout M5. This results 168 in an Ara-C induced reduction of the transition rate.
169
In M8 we replaced the complete feedback function F in M5 by F/S(x 1 ). This 170 models an Ara-C induced decreased auto-feedback of the proliferating cells. For high 171 values of x 1 , i.e. when (1) holds, this results in a decreased killing of proliferative cells. 172 For values x 1 > 0 below that boundary, we get a decreased positive proliferation rate.
173
In M9 we replaced both the complete feedback function F by F/S(x 1 ) and the 174 proliferation exponent γ by γ S(x 1 ). Again, depending on x 1 either the killing or the 175 proliferation rate of x pr are decreased by F/S(x 1 ). In addition, the impact depends on 176 September 26, 2018 7/39 whether the WBC count is below or above the baseline: for x ma < B we have an 177 increased killing/proliferation rate (B/x ma ) γ S(x1) > (B/x ma ) γ and vice versa.
178
In M10 we replaced the proliferation exponent γ in M5 by γ S(x 1 ). This is 179 motivated by the observation that the feedback term with exponent γ is related to the 180 endogenous G-CSF [6] , and the assumption that higher concentrations of Ara-C coincide 181 with activation of macrophages and hence increased G-CSF secretion. In contrast to M9 182 the function F itself is not scaled. Like in M9, the γ S(x 1 ) scaling results in an increase 183 of killing/proliferation rates for WBC counts below the baseline, and a decrease else.
184
In M11 we replaced the quotient B/x ma by a comparison between cells in the bone 185 marrow and their baseline value. We estimated that about 1% of the WBC precursor 186 cells in the bone marrow are in the proliferating compartment x pr , and 99% in the 187 transition compartment x tr .
188
In M12 we combined the extensions from M10 and M11. 
216
The ordinary differential equations comprise states (drug concentrations and cell 217 counts), control (chemotherapy schedule), and model parameters. Model parameters are 218 variable numbers and the main tool for personalisation. In the interest of identifiability 219 we calculated values for PK parameters a priori from published data [26] and fixed 220 others to values from the literature. We then used individual and population parameter 221 estimations to obtain the remaining model parameters B, slope, k tr , and γ plus a 222 varying initial condition approach such that measured WBC counts from one or several 223 cycles were fitted in an optimal way. Once the model parameters have particular values, 224 the model is called PM. A PM can be solved numerically, resulting in calculated cell 225 counts at arbitrary time points that can be used for further analysis.
Prediction & Cross-Validation
227
The PMs were then used to predict (simulate) and cross-validate WBC counts for the 228 last CC of 14 patients for whom at least two consecutive CCs are available.
229
Additionally, we calculated predicted t rec values from our 42 PMs (see Clinical Data 230 & Personalisation) applying D123 and D135 schedules and compared the descriptive 231 statistics with published average t rec values from a subset of data (367 CCs of 208 AML 232 patients, no G-CSF support) of the AMLSG 07-04 trial in which the schedules D123 233 and D135 after 7+3 regimen were analysed [30] . The published AMLSG 07-04 [30] trial 234 does not provide WBC counts to obtain new PMs, therefore we used the median of 235 observed t rec values for D123 and D135 Ara-C schedules. In the interest of a fair 236 comparison (i.e., to avoid comparison with the value 0) we excluded five out of 42 PMs 237 for which at least one prediction (M1-M12 with either D123 or D135) resulted in no 238 WBC counts below the threshold value. Further, we predicted t rec values for two Ara-C 239 schedules in which a constant administration of Ara-C throughout days 1-5, with either 240 100 mg/m 2 or 400 mg/m 2 was given. These schedules, together with D135, have been 241 clinically analysed for 1088 AML patients (median 52, 568 male) by Mayer et al. [3] , 242 and the superiority of D135 with respect to disease-free survival rates and remaining in 243 continuous complete remission after four years has been shown but no t rec values were 244 reported. Finally, we analysed the effect of the inter-individual PK variability on the 245 t rec values derived by the models M3 and M10 (with I1). We applied schedules D123 246 and D135 with fixed population parameter values for B, slope, k tr , and γ and 247 performed 500 simulations each with randomly chosen values from the inter-individual 248 variability (IIV) for the PK parameters clearance and central volume.
249
All experiments were performed to analyse the 12 proposed models with respect to 250 WBC count and t rec predictability. practice. We analysed the impact of the treatment timing on the individual nadir values. 255 For each of the 14 patients, for whom at least two consecutive CCs were available, the 256 nadir of the last CC was compared to 20 simulated nadirs. These nadirs resulted from 257 simulations using the patient's PMs (second row of Table 2 ) in which the timing of the 258 last CC was varied daily with the maximal starting variation of 10 days earlier or later. 259
Results
260
Accuracy of PMs with fixed Ara-C schedule 261 Table 2 shows statistics for PMs derived from M1-M12, for a pure estimation (using all 262 available WBC counts to personalise the model) and for a cross-validation (using all but 263 the last CC for personalisation). The accuracies depend strongly on the number of 264 compartments and initial condition strategy (M1-M5), but are stable against modelling 265 uncertainty with respect to possible effects of Ara-C (RMSE values for prediction 266 between 0.997 and 0.908 for M5-M12). These values were even better when the 267 standard schedule D135 was applied in the estimated and predicted cycles. Carlo simulations (for more information see Appendix S1). The uncertainty reduces 273 when more WBC counts are used, and the accuracy increases.
274
The WBC counts around the nadir are explained well by all models for fixed Ara-C 275 schedules (either D135 or D123), as shown in Fig 3a-d for two exemplary patients and 276 in Fig S2-S3 hematological recovery for D123 (D135). All three models assume that the proliferation 281 speed γ depends on the Ara-C concentration. This modelling assumption is visualised 282 in a different way for M5, M10 and M12 in Fig S4- Comparison of personalised models (PMs) based on M1-M12 and white blood cell (WBC) data. Patient with three D135 cycles (left) and patient P D123 with two D123 cycles (right), as indicated on the x-axis. The PMs exemplify reproducability (first row), predictability (second row) and simulation of a different schedule in prediction than estimation (third row). Table 3 shows results for a comparison of predicted and measured t rec values. We been qualitatively confirmed by the predicted t rec values from the population approach 296 (see Table S4 ). 
305
The simulation study analysing the effect of the PK variability on the resulting 306 recovery times of schedules D123 and D135 for models M3 and M10 (with I1) revealed 307 that model M10 was more sensitive to different high-dose Ara-C treatment schedules 308 compared to model M3 despite the high inter-individual PK variability. This was 309 verified in Fig S9 presenting boxplots of 500 simulated t rec values for both models and 310 schedules with IIV on the PK.
311
Schedule Timing
312
We analysed the impact of different treatment starts of the last CCs with respect to 313 subsequent nadir values. A comparison to the clinically observed nadir values indicated 314 a large potential for clinical improvement, i.e., a higher nadir value due to a different 315 treatment timing (see Fig 4(a) ). Fig 4(b) exemplarily shows the WBC dynamics for 316 different treatment timings. Earlier (later) starts resulted in sequentially higher (lower) 317 nadir values.
318
Discussion
319
High-density WBC counts from 23 AML patients were collected and used to personalise 320 12 mathematical models and analyse their prediction accuracy with respect to different 321 modelling hypotheses and treatment schedules. The high prediction accuracies of the 322 PMs, especially around the nadir, confirm previous claims [4, 12] that the general 323 approach of in-silico studies can be used for clinical decision support, e.g. to monitor 324 and predict WBC dynamics.
325
In combination with clinical expertise on the impact of schedules on relapse 326 probabilities, this might have an important clinical impact via altered treatment 327 schedules which might eventually result in improved survival rates. To evaluate or even 328 optimise the dosage of Ara-C, PMs may not be appropriate, though. We showed that 329 an analysis based on a fixed chemotherapy schedule can not discriminate between 330 different modelling hypotheses. The agglomerative nature of the mathematical models 331 leads to a choice of model parameters that is not only personalised to the patient, but 332 also to the applied schedule. Therefore, we used, different schedules for personalisation 333 and prediction to overcome this problem and to allow discrimination of the models. Shown are the median, standard deviation, minimum and maximum (in brackets) of trec, the leukopenia time t leu (the number of days with WBC count ≤ 1 G/L) and nadir for D123 and D135 schedules. The first two rows show values from two independent clinical studies that serve as a comparison. The second part of the table shows prediction results. Predictions were calculated with PMs from our clinical data with underlying mathematical models M1-M12. Model M5 explained well the outcome of schedule D135, but showed a significant mismatch of more than three days for schedule D123. The predictions using the extended model M10 were better for schedule D123. See also Fig 3e-f for an illustrated comparison between M5 and M10. Model M9 and M12 were also promising, but we focused on M10 applying Ockam's razor.
in models M5-M12 and enabled to find the suitable model assumption considered in 336 M9, M10, and M12. In our opinion this procedure should be routinely applied, 337 preferably using high density WBC counts for different schedules in the same patients. 338 As an alternative to such a tedious clinical study we suggest to use average t rec values 339 as a discrimination criterion for competing models. (a) Simulation study in which 20 simulated nadirs were compared with the true nadir of the last CC for the 14 patients who have more than one CC. The simulated nadirs were computed by using the patient's PM (second row of Table 2 ) and varying the start of the last CC daily with the maximal starting variation of 10 days earlier or later. (b) Exemplary variation of the CC start for one patient. An earlier (later) start results in a larger (lower) nadir.
Comparing our clinical data and the AMLSG 07-04 trial with respect to t rec in 341 Summarising, we extended the gold-standard model for myelosuppression [6] to the 354 most important component in consolidation therapy [2, 13] , Ara-C, and showed that one 355 modelling assumption was important for a faster WBC count recovery for D123 356 schedules. In models M9, M10, and M12 we assumed that the Ara-C concentration has 357 a direct impact on the proliferation speed. As stated above, such a modelling 358 assumption has an agglomerative nature and the underlying physiological processes are 359 still unknown. We speculate that a high Ara-C concentration might lead to an increased 360 number of cell deaths and thereby induces phagocytosis and macrophage activation, The authors declare no competing financial interests.
Supporting Information
390
Appendix S1 Additional methods.
391
Table S1 Terminology and potentially confusing synonyms. Expressions that 392 are also used in the manuscript are in italic.
393
Table S2 Comparison of model predictions for low-dose treatment 394 schedules. As in Table 3 predicted values for different treatment schedules are shown, 395 based on underlying mathematical models M1-M12. Shown are the values of median, 396 standard deviation, minimum and maximum (in brackets) for two low-dose schedules.
397
Both assume a constant administration of drugs throughout days 1 to 5, with either 398 100 mg/m 2 or 400 mg/m 2 body surface. We do not have clinical data to compare these 399 predictions, but they give additional insight on the possibility to discriminate models 400 M1-M12 and a general trend showing that independent of the modelling assumptions 401 both low-dose schedules result in slower white blood cell recovery and lower nadirs than 402 D135 or D123. This has been clinically observed [3] . (Two further personalised cycles 403 were excluded because for some models no recovery after chemotherapy was observed) 404 Table S3 Model constants, patient-specific constants, and units of model 405 parameters. The values were used to obtain personalised mathematical models. The 406 constants were determined from published data [26] and applied to all patients. To 407 shorten notation we also used c V = 1 Vc M Mcyt . The patient-specific infusion times and 408 dosages that define a treatment schedule were modified for simulation and optimisation 409 of different schedules. The range shows minimum and maximum values of all considered 410 data in the clinical study. Figure S1 Goodness-of-fit plot for all but three (because of WBC counts 417 greater 1) measured and calculated t rec values for model M10. The measured 418 t rec values are slightly higher due to the coarser measurement grid.
419 Figure S2 Cross-validation of predicted white blood cell (WBC) counts 420 from personalised models (PMs) M1-M12 and measured WBC counts for 421 six patients treated with D135. All but one cycle were used for personalisation and 422 the last cycle for cross-validation. For patients (a)-(e) the PMs can predict the WBC 423 count decrease after Ara-C administration in the last cycle where models M10 and M12 424 have a slower WBC recovery than M5. For patient (f) the WBC recovery from the PMs 425 starts to early compared to the measured WBC counts. 
